Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
USA
International
Media and Investors Resources
Press Release, 20 October 2016
Kuros Biosciences' KUR-112 Receives Rare Pediatric Disease Designation
Press Release, 29 September 2016
Kuros Biosciences Reports Financial Results for First Half-Year of 2016
Kuros Interim Results, 2016
English version
Cytos Interim Results, 2015
English version
Press Release, 30 August 2016
Arbutus terminates license agreement for VLP platform for the treatment of hepatitis B infections
Press Release, 10 August 2016
Kuros appoints Philippe Saudan as Chief Development Officer